LATEST ANNOUNCEMENT

CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO ADVANCE CELL THERAPY PROGRAMS

Financing round was significantly oversubscribed by existing investors and new private investors. Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline...